(Q51753740)

11 April 2018

title

Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model. (English)

1 reference

11 April 2018

11

Akio Matsubara

1 reference

11 April 2018

author name string

Naoto Kamiya

1

1 reference

11 April 2018

Hiroyoshi Suzuki

2

1 reference

11 April 2018

Kensaku Nishimura

3

1 reference

11 April 2018

Motohiro Fujii

4

1 reference

11 April 2018

Takatsugu Okegawa

5

1 reference

11 April 2018

Tadashi Matsuda

6

1 reference

11 April 2018

Tatsuo Morita

7

1 reference

11 April 2018

Yoshio Takihana

8

1 reference

11 April 2018

Seiichiro Ozono

9

1 reference

11 April 2018

Mikio Namiki

10

1 reference

11 April 2018

Tomohiko Ichikawa

12

1 reference

11 April 2018

Tsuneharu Miki

13

1 reference

11 April 2018

publication date

9 February 2014

1 reference

11 April 2018

Japanese Journal of Clinical Oncology

published in

1 reference

11 April 2018

volume

44

1 reference

11 April 2018

issue

3

1 reference

11 April 2018

page(s)

263-269

1 reference

11 April 2018

Current topics and perspectives relating to hormone therapy for prostate cancer

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

Secondary hormonal therapy for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

Hormone-refractory (D3) prostate cancer: refining the concept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT230

21 January 2018

Identifiers

DOI

10.1093/JJCO/HYT230

1 reference

11 April 2018

1 reference

11 April 2018